Clinical Follow-up of Direct/Indirect Bridge, Orthodontic and Periodontal Splint by Using Fibre-reinforced Composite
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02343796|
Recruitment Status : Unknown
Verified February 2017 by Ovul Kumbuloglu, Ege University.
Recruitment status was: Active, not recruiting
First Posted : January 22, 2015
Last Update Posted : February 10, 2017
|Condition or disease||Intervention/treatment||Phase|
|Tooth Loss Tooth Mobility||Other: Fibreglass reinforced composite restoration-everStick Device: everStick||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Follow-up of Direct/Indirect Bridge, Orthodontic and Periodontal Splint Applications by Using Fibre-reinforced Composite.|
|Study Start Date :||June 2003|
|Actual Primary Completion Date :||December 2014|
|Estimated Study Completion Date :||December 2018|
Experimental: Fibre-reinforced composite
Fibreglass reinforced composite restoration-everStick as a medical device intervention will be applied on each subject by using either direct or indirect method. everStick (GC, Belgium) will be used as a fibre reinforcement material.
Other: Fibreglass reinforced composite restoration-everStick
For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
- Number of participants with clinical survival of the applied restoration, splint or retainer, as indicated by observations for any fractures on composite. [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02343796
|Izmir, Turkey, 35100|
|Principal Investigator:||Ovul Kumbuloglu, Assoc Prof||Ege University|